Affimed to Present at Upcoming Investor Conferences

Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company, announced its participation in several investor conferences in September 2022. Key events include:

• Wells Fargo Healthcare Conference on September 7, 2022, at 3:10 p.m. EDT in Boston, MA, with a webcast available.
• Citi’s Annual BioPharma Virtual Conference on September 8, 2022, for one-on-one meetings in Boston, MA.
• Morgan Stanley’s Global Healthcare Conference on September 13, 2022, for one-on-one meetings in New York, NY.
• Jefferies Cell and Genetic Medicine Summit on September 29, 2022, for one-on-one meetings in New York, NY.

HEIDELBERG, Germany, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the Company’s management will participate in the following investor conferences during the month of September 2022.

2022 Wells Fargo Healthcare Conference (September 6-9, 2022)
Date: Wednesday, September 7, 2022
Presentation Time: 3:10 p.m. Eastern Daylight Time
Webcast: https://www.affimed.com/investors/webcasts-and-corporate-presentation/
Location: Boston, MA

Citi’s 17^th Annual BioPharma Virtual Conference (September 6-8, 2022)
Date: Thursday, September 8, 2022
Only one-on-one meetings
Location: Boston, MA

Morgan Stanley’s 20^th Annual Global Healthcare Conference (September 12-14, 2022)
Date: Tuesday, September 13, 2022
Only one-on-one meetings
Location: New York, NY

Jefferies Cell and Genetic Medicine Summit (September 29-30, 2022) 
Date: Thursday, September 29, 2022
Only one-on-one meetings
Location: New York, NY

For more information or to schedule a one-on-one meeting with Affimed’s management, please contact your event representative or Alex Fudukidis via email at a.fudukidis@affimed.com or phone at +1 (917) 436-8102.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK^® platform allows innate cell engagers to be designed for specific patient populations. The company is developing single and combination therapies to treat hematologic and solid tumors. The company is currently enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T cell lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. For more information, please visit www.affimed.com.

Affimed Investor Contact

Alexander Fudukidis
Director, Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102

FAQ

What events is Affimed (AFMD) participating in during September 2022?

Affimed will participate in the Wells Fargo Healthcare Conference, Citi’s Annual BioPharma Virtual Conference, Morgan Stanley’s Global Healthcare Conference, and Jefferies Cell and Genetic Medicine Summit.

When is the Wells Fargo Healthcare Conference presentation by Affimed?

Affimed's presentation at the Wells Fargo Healthcare Conference is scheduled for September 7, 2022, at 3:10 p.m. EDT.

Where will Affimed hold its one-on-one meetings in September 2022?

Affimed will hold one-on-one meetings in Boston, MA, for the Citi conference and in New York, NY, for the Morgan Stanley and Jefferies conferences.

What is the focus of Affimed's immuno-oncology research?

Affimed focuses on developing therapies that harness the innate ability to fight cancer, targeting hematologic and solid tumors.

How can investors schedule a meeting with Affimed management?

Investors can schedule meetings with Affimed management by contacting their event representative or reaching out to Alex Fudukidis via email.